EGFR and non-small cell lung carcinoma: We used MK2206, which is an allosteric AKT inhibitor, to suppress the phosphorylation of AKT in four EGFR-mutant NSCLC cell lines (PC9, NCI-H1975, HCC827, and HCC4006) (Figure 6A).